Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Myozyme Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The historical growth was driven by the recognition of Pompe disease as a manageable condition, regulatory approvals granted for enzyme replacement therapies, the expansion of initiatives aimed at raising awareness about rare diseases, advancements in recombinant enzyme technologies, and the creation of specialized treatment centers.
The growth projected for the forecast period is fueled by higher investments in rare disease research, an increased need for next-generation enzyme therapies, the expansion of individualized treatment strategies, a stronger emphasis on managing rare diseases in pediatric populations, and improvements in biologics production methods. Among the key trends shaping this period are the growing adoption of enzyme replacement therapies, a heightened focus on solutions for rare disease treatment, rising demand for sustained management of Pompe disease, the expansion of biologic drug manufacturing capabilities, and better patient access initiatives for orphan drugs.
Download A Free Sample Report For Comprehensive Market Insights:
Myozyme Market Growth Momentum: Which Factors Are Influencing Demand?
The increasing incidence of rare genetic disorders is expected to drive the growth of the myozyme market going forward. Rare genetic disorders are uncommon inherited conditions resulting from gene mutations, impacting only a small portion of the population. The increasing incidence of rare genetic disorders can be attributed to genetic mutations, improved genetic testing, and population growth. Myozyme helps manage the symptoms of Pompe disease by replacing the deficient enzyme, which can extend patients’ lives and improve their quality of life. As more individuals with Pompe disease receive treatment, it leads to longer survival rates and better health outcomes, further driving the demand for myozyme in managing these disorders. For instance, in July 2025, according to the Adult Polyglucosan Body Disease (APBD) Research Foundation, a US-based nonprofit organization dedicated solely to advancing research, a recent study on 1,4-alpha-glucan branching enzyme 1 (GBE1)-related rare genetic diseases updated the global prevalence estimate from 1 in 325,000 in 2022 to 1 in 236,000 in 2025, suggesting about 34,000 people worldwide could be affected, reflecting improved detection and data on these rare disorders. Therefore, the increasing incidence of rare genetic disorders is driving the growth of the myozyme market.
Myozyme Market Driver: Rise In Healthcare Investment Driving The Growth Of The Market
The rise in healthcare investment is expected to propel the growth of the myozyme market going forward. The investment in healthcare infrastructure is an allocation of resources to develop, improve, and maintain the physical, technological, and organizational systems necessary for effective healthcare delivery. Healthcare investment is increasing due to several factors, such as growing demand, pandemic preparedness, improving health outcomes, and the need for better access and equity. The rise in healthcare investment enhances the ability to develop specialized drugs such as myozyme and supports research, development, and accessibility of life-saving treatments for rare diseases. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the rise in healthcare investment is driving the myozyme market.
Myozyme Market Driver: Rise In The Adoption Of Telemedicine Driving The Growth Of The Market
The rise in the adoption of telemedicine is expected to drive the growth of the myozyme market going forward. Telemedicine refers to using digital communication technologies to provide healthcare services remotely, including consultations, diagnoses, and treatment monitoring. The rise in the adoption of telemedicine is driven by factors such as increasing access to health care, greater convenience for patients, and significant cost savings for both providers and patients. Telemedicine enables more frequent and convenient consultations between patients and healthcare professionals. Early diagnosis of conditions like Pompe disease, which Myozyme treats, is crucial for effective treatment. Telemedicine can facilitate quicker diagnoses, thus increasing demand for Myozyme as more patients begin treatment earlier. For instance, in February 2025, according to the American Hospital Association, a US-based national organization representing and supporting US hospitals and health systems, in Q4 2023, more than 12.6% of Medicare beneficiaries utilized telehealth services. Therefore, the rising adoption of telemedicine is driving the growth of the myozyme market.
Myozyme Market Segment Landscape And Growth Potential
The myozyme market covered in this report is segmented –
1) By Indication: Treatment of Pompe Disease, Other Glycogen Storage Disorders
2) By Age Group: Pediatric Patients, Adult Patients
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies, Government And Public health Programs
4) By End-User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings
Myozyme Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the myozyme market are Sanofi S.A.
Access The Complete Myozyme Market Report:
Myozyme Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the myozyme market in 2025. The regions covered in the myozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model